It is known that bone mineral density (BMD) is low in men who are hypogonadal. However, the rate and sites of bone loss following testosterone deficiency are not known. The resulting hypogonadism after GnRH analog therapy for the treatment of prostate cancer allows us to examine bone loss and bone r...
Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.
No comments yet
Be the first to share your thoughts!